Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, has announced, in partnership with its collaborators, early clinical data from two product candidates.
JCAR018 is a chimeric antigen receptor (CAR) T cell product candidate targeting CD22, and had data from a phase I trial in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r ALL). JTCR016, a T cell receptor (TCR) cell product candidate targeting Wilms tumor-1 (WT-1), had data from a phase I trial in patients with acute myelogenous leukemia (AML) at high risk of relapse following an allogeneic hematopoietic stem cell transplant and patients with either mesothelioma or non-small cell lung cancer.
“As we advance our CD19-directed portfolio, we are encouraged by the early signs of clinical activity from product candidates against different targets,” said Mark J. Gilbert, M.D., Juno’s chief medical officer. “The data from JCAR018 suggest two paths to improve outcomes—use in patients with CD19 negative disease and a combination of CD19 and CD22 to decrease the risk of resistant cells and increase the percentage of patients that demonstrate a long-term durable remission in B cell malignancies. Additionally, JTCR016 continues to show an encouraging safety profile and signals of clinical activity, including evidence of tumor reduction as well as significant T cell expansion and persistence in a patient with mesothelioma.”
Terry J. Fry, M.D., investigator, Pediatric Oncology Branch and head of Hematologic Malignancies Section, National Cancer Institute, National Institutes of Health, reported on CD22-directed CAR T cell therapy (JCAR018) in pediatric and young adult patients with r/r B-cell ALL. Key takeaways include:
Phil Greenberg, M.D., head of Program in Immunology at the Fred Hutchinson Cancer Research Center, and professor, Medicine/Oncology and Immunology, University of Washington, reported on WT-1 TCR cell therapy (JTCR016) in refractory mesothelioma and AML. Key takeaways include: